GET DAILY SIGNALSBeyond Air (XAIR): Cylinder-Free Nitric Oxide Delivery and Its Commercial Path
Key Takeaways
- XAIR is the Nasdaq ticker for Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) therapies.
- The company's flagship product, LungFit PH, is a cylinder-free system that generates inhaled nitric oxide from ambient air, approved to treat persistent pulmonary hypertension of the newborn (PPHN).
- Beyond Air operates through three segments: Beyond Air, Beyond Cancer, and NeuroNOS, spanning respiratory medicine, oncology, and neurological disorders.
- As a small, early-revenue business, Beyond Air has historically reported net losses and depends on continued financing and regulatory milestones to fund growth.
Introduction
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on the therapeutic uses of nitric oxide (NO), a molecule the body produces naturally to help regulate blood flow and immune response. Its key innovation is the LungFit platform, which creates NO on demand from ambient air instead of relying on large, pressurized cylinders. I follow XAIR because the company combines a novel delivery method with established clinical needs, and its pipeline spans respiratory care, oncology, and neurology.
Company Background and Operations
Beyond Air was founded in 2011 and is based in Garden City, New York. It was previously known as AIT Therapeutics, Inc. before adopting its current name in June 2019. The company is led by Chief Executive Officer Robert Scott Goodman.
Its business centers on selling and leasing devices that deliver inhaled nitric oxide. The first commercial product, LungFit PH, received premarket approval from the FDA in June 2022 for treating term and near-term newborns with persistent pulmonary hypertension of the newborn. It also holds a European CE Mark for distribution in the EU.
Traditional nitric oxide systems depend on high-pressure cylinders that require storage, transport, and frequent replacement. LungFit uses a patented plasma process to generate the gas from room air, which can reduce hospital inventory demands, improve safety by removing certain purging requirements, and lower operating costs. Revenue comes mainly from placing LungFit PH systems and their ongoing use in hospitals.
Segments and Product Pipeline
The company divides its work into three segments:
- Beyond Air: The main respiratory unit built around LungFit PH. Work continues on a second-generation version, LungFit PRO for serious viral lung infections, and LungFit GO for chronic conditions such as nontuberculous mycobacteria (NTM).
- Beyond Cancer: An affiliate exploring ultra-high-concentration nitric oxide as a possible treatment for solid tumors, including combinations with immunotherapy.
- NeuroNOS: A program developing small-molecule therapies that modulate nitric oxide in the brain, with early focus on autism spectrum disorder and other neurological conditions.
Most current revenue and commercial activity remain in the respiratory segment, though the structure opens several potential growth areas.
Why Investors Follow XAIR
Investors are attracted to Beyond Air because it offers an FDA-cleared technology that meets a clear need in neonatal intensive care, and the cylinder-free design provides hospitals with a practical advantage. The inhaled nitric oxide market is established, and replacing older cylinder systems could create a lasting edge over time.
The broader pipeline in oncology and neurology widens the long-term opportunity, even though those programs are still early. International expansion through the CE Mark and distribution partners adds another avenue outside the U.S. The central story for investors is the marketed product, growing installed base, and diversified research efforts.
One thing that stands out when I reviewed recent data was how the company’s installed base is progressing; I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Risks and Important Considerations
Beyond Air faces the typical challenges of a small, early-commercial medical technology firm. It has a track record of operating losses and negative cash flow, and it relies on raising additional capital to support operations and development. Revenue is still modest compared with expenses, and growth depends on wider hospital adoption of LungFit PH.
Regulatory risk remains material. The second-generation LungFit PH and other pipeline candidates are still under review or in clinical stages, so FDA decisions or trial results can shift the outlook. The inhaled nitric oxide space includes established competitors and alternative technologies, and revenue can be uneven due to concentration among hospital customers. Early-stage oncology and neurology programs carry additional uncertainty and may take years to reach the market, if they do at all.
Using Tickeron’s AI Screener for Research
In my own analysis, I often turn to Tickeron’s AI Screener to quickly filter stocks and ETFs by technical indicators, fundamentals, volatility, trends, and AI-generated signals. It helps surface ideas that align with specific strategies without sifting through thousands of names manually. This tool has become a regular part of how I evaluate opportunities like XAIR in the medical device space.
Conclusion
Beyond Air, Inc. has moved a distinctive, cylinder-free nitric oxide platform from concept to an FDA-approved commercial product while keeping a wider pipeline across respiratory, oncology, and neurological uses. Its position rests on differentiated delivery technology that meets a real need in neonatal care, with further potential tied to future approvals and pipeline progress. At the same time, its early-stage financial profile and reliance on ongoing financing and regulatory steps make it a higher-risk name that investors should assess against their own goals and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XAIR's RSI Oscillator ascending out of oversold territory
The RSI Indicator for XAIR moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 35 of the 42 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on XAIR as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +13.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where XAIR advanced for three days, in 174 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 44 cases where XAIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
XAIR broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XAIR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.084) is normal, around the industry mean (4.142). P/E Ratio (-0.036) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.213) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. XAIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XAIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the development of nitric oxide (NO) generator and delivery system.
Industry MedicalNursingServices
Advertisement